Searched for
IMPACT OF DRUG TARIFFS
These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...
India losing investor attention to Asia’s AI-electronics surge, says DBS economistGlobal capital is shifting towards electronics and AI in Asia. India's foreign direct investment slowdown is not a major concern. Asia's ex...
Pharma exports surpass $31 billion in FY26 despite global headwindsIndian pharmaceutical exports reached over $31 billion in FY26. March saw a significant 23% drop, primarily due to a slowdown in the United...
UK exports to US slump as tariffs bite: Official dataBritish exports to the United States have fallen significantly following the imposition of US tariffs. The value of goods exported to the U...
Compliance squeeze, global scrutiny redefine India’s $30 billion pharma export playbookAs global markets prioritise quality and regulatory trust, India’s pharma sector is recalibrating beyond its traditional cost advantage.
Trump's $166 billion tariff refunds may finally be in sight as first payouts expected by May 11The Trump administration is set to issue its first tariff refunds around May 11, following the Supreme Court's ruling that the sweeping dut...
Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
India–New Zealand sign 'once-in-a-generation' FTAIndia and New Zealand signed a “once-in-a-generation” free trade agreement on Monday that gives New Delhi duty-free access to 100% of tarif...
GST 2.0 Inverted duty structure hurts FMCG, Pharma: Expert flags concernsIndian enterprises are navigating challenges posed by the Goods and Services Tax. The inverted duty scenario is particularly affecting FMCG...
Labour-intensive sectors see steep fall in exports in MarchThe fiscal year 2026 brought a mixed bag for India's exports. On one hand, engineering goods, electronics, and pharmaceuticals excelled, dr...
Biocon rolls out two biosimilars in US marketBiocon has launched two new biosimilar medicines, Bosaya and Aukelso, in the United States. These drugs treat serious bone conditions. They...
Trump pushes pharma tariffs, but exemptions limit impactThe United States has introduced tariffs on branded drug imports. However, many exemptions will limit their effect. Companies investing in ...
US tariffs on metals and pharma: Which Indian stocks are safe and which aren't: Sudip BandyopadhyayIndian equity markets face policy risks from US tariffs and West Asia conflict. These issues impact metals and pharmaceutical sectors. Expe...
Trump tariffs hit patented drugs: Jefferies, Nomura explain impact on pharma stocksThe US has slapped up to 100% tariffs on patented drugs, sparing generics and biosimilars but exposing India’s speciality pharma players. S...
Trump's 100% tariff on patented drugs has limited impact on Indian pharma, rising protectionism a concern: Syngene MDThe recent decision by US President Donald Trump to impose a 100 per cent tariff on patented pharmaceutical imports to US is unlikely to ca...
India largely shielded from US tariffs on patented drugs due to generic export strength: GTRINew US tariffs on patented drugs will not significantly impact India. The country mainly exports affordable generic medicines to America. T...
Pharma calls in sick after Trump’s 100% tariff threatPharma stocks fell Thursday after reports of US President Donald Trump mulling 100% tariffs on imported branded and patented medicine maker...